Cardiovascular Drugs Practice Questions

Q: A patient with hypertension was treated with propranolol. Although it controlled hypertension, it reduced the resting heart rate to 50/min. Which of the following beta-blockers can be used as an effective substitute that does not cause bradycardia?

Pindolol. ### Explanation The correct answer is **Pindolol**. **1. Why Pindolol is correct:** The underlying medical concept here is **Intrinsic Sympathomimetic Activity (ISA)**, also known as partial agonist activity [1]. * **Mechanism:** Pindolol is a non-selective beta-blocker that acts as a partial agonist [1]. While it blocks the effects of endogenous catecholamines (lowering blood pressure), it simultaneously provides a low level of background stimulation to the beta-1 receptors. * **Clinical Effect:** This prevents the heart rate from dropping excessively during rest. Therefore, pindolol is the drug of choice for hypertensive patients who develop symptomatic bradycardia with pure beta-blockers. **2. Why the other options are incorrect:** * **Atenolol & Bisoprolol:** These are selective $\beta_1$ blockers (cardioselective). They lack ISA and are well-known for causing a significant reduction in heart rate (bradycardia) as a primary side effect [2], [3]. * **Labetalol:** This is a combined $\alpha_1$ and non-selective $\beta$ blocker [3]. While it is used in hypertensive emergencies and pregnancy, it does not possess ISA and can still cause a decrease in heart rate, though often less than pure beta-blockers due to its alpha-blocking vasodilatory effect. **3. High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for ISA:** "**P**alpitation **A**nd **C**ardiac **A**cceleration" (**P**indolol, **A**cebutolol, **C**artelol, **A**lprenolol). * **Avoid in Post-MI:** Beta-blockers with ISA (like Pindolol) are generally **avoided** in patients with a history of myocardial infarction or angina because they do not provide the same degree of "cardiac rest" as pure antagonists. * **Lipid Neutrality:** Beta-blockers with ISA have a more favorable profile on serum lipids compared to traditional beta-blockers.

Q: All of the following are used in the treatment of pulmonary hypertension EXCEPT:

Beta blockers. **Explanation:** The primary goal in treating Pulmonary Arterial Hypertension (PAH) is to reduce pulmonary vascular resistance (PVR) through vasodilation. **Beta-blockers (Option D)** are generally **contraindicated** or avoided in PAH. This is because they exert negative inotropic and chronotropic effects, which can decrease cardiac output and potentially worsen right heart failure—the leading cause of death in these patients. **Analysis of Options:** * **Endothelin Receptor Antagonists (Option A):** Drugs like **Bosentan** (non-selective) and **Ambrisentan** (ET-A selective) block endothelin-1, a potent vasoconstrictor and smooth muscle proliferator, making them a cornerstone of PAH therapy. * **Phosphodiesterase-5 (PDE-5) Inhibitors (Option B):** **Sildenafil** and **Tadalafil** increase cGMP levels, leading to nitric oxide-mediated vasodilation of the pulmonary vasculature. * **Calcium Channel Blockers (Option C):** High-dose CCBs (e.g., **Nifedipine, Diltiazem**) are used specifically in a subset of patients who show a positive "vasoreactivity test" during right heart catheterization. **Clinical Pearls for NEET-PG:** 1. **Prostacyclin Analogues:** Epoprostenol (IV), Treprostinil, and Iloprost are potent vasodilators used in advanced PAH. 2. **Soluble Guanylate Cyclase (sGC) Stimulator:** **Riociguat** is a high-yield drug used for both PAH and Chronic Thromboembolic Pulmonary Hypertension (CTEPH). 3. **Side Effects:** Bosentan is associated with **hepatotoxicity** (requires LFT monitoring) and is highly teratogenic. 4. **Drug of Choice:** For patients who are vasoreactive, CCBs are the initial choice; for others, ERA or PDE-5 inhibitors are preferred.

Q: What is the initial drug of choice for a newly detected hypertension in a 42-year-old male with a history of calcium stones?

Chlorthalidone. **Explanation:** The correct answer is **Chlorthalidone**. This question tests the ability to select an antihypertensive based on comorbid conditions—a high-yield topic for NEET-PG. **Why Chlorthalidone is correct:** Thiazide and thiazide-like diuretics (such as Chlorthalidone and Hydrochlorothiazide) are unique because they **decrease urinary calcium excretion**. They act on the distal convoluted tubule to inhibit the Na+/Cl- symporter, which indirectly enhances Ca2+ reabsorption. In a patient with a history of calcium stones (nephrolithiasis), reducing the concentration of calcium in the urine prevents stone formation while simultaneously managing blood pressure. Chlorthalidone is often preferred over HCTZ due to its longer half-life and superior evidence in reducing cardiovascular events. **Why other options are incorrect:** * **Furosemide (Loop Diuretic):** Unlike thiazides, loop diuretics **increase** urinary calcium excretion ("Loops lose calcium"). This would increase the risk of stone formation in this patient. * **Losartan (ARB):** While an excellent first-line antihypertensive (especially in diabetics), it has no specific benefit for preventing calcium stones. * **Atenolol (Beta-blocker):** No longer considered first-line for uncomplicated hypertension unless there is a specific cardiac indication (e.g., post-MI or heart failure). **Clinical Pearls for NEET-PG:** * **Thiazides:** Cause Hyper**GLUC** (Hyper**G**lycemia, Hyper**L**ipidemia, Hyper**U**ricemia, Hyper**C**alcemia). * **Loop Diuretics:** Used for edema and acute heart failure; cause **hypo**calcemia. * **First-line HTN drugs (JNC-8):** Thiazides, ACE inhibitors, ARBs, or Calcium Channel Blockers. * **Drug of choice for HTN with Benign Prostatic Hyperplasia (BPH):** Prazosin (Alpha-1 blocker).

Q: Which of the following drugs hyperpolarizes AV nodal tissue, is used in PSVT, and has short-lasting adverse effects?

Adenosine. ### Explanation **Correct Answer: C. Adenosine** **Mechanism and Rationale:** Adenosine is the drug of choice for the acute termination of Paroxysmal Supraventricular Tachycardia (PSVT). It acts by binding to **A1 receptors** on the AV node, which activates G protein-coupled inward-rectifying potassium channels (GIRK). This leads to an **efflux of Potassium (K+)**, causing **hyperpolarization** of the nodal tissue. Simultaneously, it decreases cAMP, inhibiting Calcium (Ca2+) influx. The result is a transient but potent suppression of AV nodal conduction, "resetting" the rhythm. **Why the other options are incorrect:** * **Verapamil (CCB):** While used for PSVT, it works by blocking L-type Calcium channels (decreasing the slope of Phase 0). It does not cause hyperpolarization and has a much longer half-life (hours) compared to Adenosine. * **Digoxin:** It increases vagal tone to slow the AV node but is primarily used for rate control in Atrial Fibrillation. It does not cause hyperpolarization; rather, it can increase intracellular Calcium. * **Propranolol (Beta-blocker):** It slows the heart rate by decreasing the Phase 4 depolarization slope in the SA node. It is used for prophylaxis rather than acute termination of PSVT and lacks the rapid "on-off" effect of Adenosine. **High-Yield Facts for NEET-PG:** * **Ultra-short half-life:** <10 seconds (due to rapid uptake by RBCs and endothelial cells). * **Administration:** Must be given as a **rapid IV bolus** followed by a saline flush, preferably through a central or large peripheral vein. * **Adverse Effects:** Flushing, chest pain, and dyspnea. These are distressing but **short-lasting** (seconds). * **Drug Interactions:** Effects are **potentiated by Dipyridamole** and **antagonized by Theophylline/Caffeine** (adenosine receptor blockers). * **Contraindication:** Bronchial asthma (can cause bronchospasm) and high-grade heart block.

Q: Digoxin increases cardiac contractility by directly engaging in which of the following mechanisms?

Inhibiting myocardial Na+/K+-ATPase. **Explanation:** Digoxin, a cardiac glycoside, increases cardiac contractility (positive inotropy) through a well-defined sequence of ionic shifts. **Mechanism of Action (Why D is correct):** The primary molecular target of Digoxin is the **Na+/K+-ATPase pump** located on the sarcolemma of myocardial cells. By binding to the extracellular alpha subunit of this pump, Digoxin inhibits the active transport of Na+ out of the cell and K+ into the cell. This leads to an **increase in intracellular Na+**. The rise in intracellular Na+ reduces the concentration gradient that drives the **Na+/Ca2+ exchanger (NCX)**. Consequently, the efflux of Ca2+ is diminished, leading to increased intracellular Ca2+ levels. This excess Ca2+ is sequestered into the Sarcoplasmic Reticulum (SR) and released during subsequent action potentials, enhancing actin-myosin cross-bridge formation and force of contraction. **Analysis of Incorrect Options:** * **A. Inhibiting myocardial Na+/Ca2+-ATPase:** There is no such enzyme as Na+/Ca2+-ATPase; the Na+/Ca2+ exchanger (NCX) is a secondary active transporter, not a primary ATPase. * **B. Activating L-type Ca2+ channels:** This is the mechanism for drugs like Bay K 8644. Digoxin does not directly act on these channels. * **C. Inhibiting cardiac phosphodiesterase:** This is the mechanism of **Milrinone and Inamrinone**, which increase cAMP levels to improve contractility. **High-Yield NEET-PG Pearls:** * **ECG Changes:** Digoxin causes the characteristic "reverse tick" or "hockey stick" ST-segment depression (Salvador Dali sign). * **Electrolyte Interactions:** **Hypokalemia** predisposes to Digoxin toxicity because K+ and Digoxin compete for the same binding site on the Na+/K+-ATPase pump. * **Antidote:** Digibind (Digoxin-specific Fab fragments). * **Therapeutic Range:** Narrow (0.5–2 ng/mL). Toxicity often presents with gastrointestinal symptoms and xanthopsia (yellow-green vision).

Q: Cardioselective beta blockers are contraindicated in which of the following conditions?

II & III degree heart block. **Explanation:** The core pharmacological action of beta-blockers involves the inhibition of $\beta_1$ receptors in the heart, leading to negative inotropic (force), chronotropic (rate), and dromotropic (conduction velocity) effects. **Why Option B is Correct:** In **II and III-degree heart blocks**, the conduction of impulses from the atria to the ventricles is already impaired. Beta-blockers further depress the **Atrioventricular (AV) node** conduction. This can exacerbate the block, potentially leading to complete heart block, severe bradycardia, or asystole. Therefore, they are strictly contraindicated regardless of their selectivity. **Why Other Options are Incorrect:** * **A & C (COPD and Asthma):** While *non-selective* beta-blockers are contraindicated due to $\beta_2$ blockade causing bronchospasm, **cardioselective** ($\beta_1$ specific) blockers (e.g., Metoprolol, Atenolol) can be used with extreme caution in stable COPD or mild asthma if the cardiac benefit outweighs the risk. They are not an absolute contraindication compared to heart block. * **D (Tachycardia):** Beta-blockers are actually a **treatment** for tachycardia (especially sinus tachycardia and supraventricular arrhythmias) because they reduce the heart rate. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for Cardioselective ($\beta_1$) blockers:** *"New Beta Blockers Are Very Exclusive"* (Nebivolol, Betaxolol, Bisoprolol, Acebutolol, Atenolol, Valolol, Esmolol, Metoprolol). * **Esmolol** is the shortest-acting beta-blocker (half-life ~9 mins), used IV for hypertensive emergencies. * **Absolute Contraindications:** Severe bradycardia, cardiogenic shock, overt heart failure, and advanced heart block. * **Prinzmetal Angina:** Beta-blockers are contraindicated as they can cause unopposed alpha-mediated coronary vasoconstriction.

Q: Which of the following antihypertensives was once used as an antipsychotic?

Reserpine. **Explanation:** **Reserpine** is the correct answer. It is an alkaloid derived from the plant *Rauwolfia serpentina*. * **Mechanism:** Reserpine irreversibly blocks the **Vesicular Monoamine Transporter (VMAT)**. This prevents the storage of neurotransmitters like norepinephrine, dopamine, and serotonin in synaptic vesicles, leading to their depletion. * **Clinical Use:** By depleting norepinephrine, it acts as an antihypertensive. By depleting dopamine and serotonin in the CNS, it was historically used as an **antipsychotic** to treat schizophrenia. However, its use is now obsolete due to the severe side effect of **suicidal depression**. **Incorrect Options:** * **Atenolol:** A selective $\beta_1$ blocker. It is hydrophilic, does not cross the blood-brain barrier effectively, and has no antipsychotic properties. * **Propranolol:** A non-selective $\beta$ blocker. While it is lipophilic and used for performance anxiety, essential tremors, and prophylaxis of migraine, it has never been used as an antipsychotic. * **Clonidine:** An $\alpha_2$ agonist that decreases sympathetic outflow. It is used in ADHD and opioid withdrawal but lacks antipsychotic efficacy. **High-Yield Pearls for NEET-PG:** 1. **Reserpine-induced Depression:** The observation that reserpine caused depression led to the "Monoamine Hypothesis" of depression. 2. **VMAT Inhibition:** Unlike Cocaine or TCAs (which act on reuptake transporters like NET/DAT), Reserpine acts on the **vesicular** transporter. 3. **Contraindication:** Never give reserpine to a patient with a history of mental depression or peptic ulcer disease (as it increases gastric acid secretion).

Q: Which one of the following drugs is associated with the development of a lupus-like syndrome, especially in patients identified as "slow acetylators"?

Procainamide. ### Explanation **Correct Option: D. Procainamide** Procainamide is a Class IA antiarrhythmic drug notorious for causing **Drug-Induced Lupus Erythematosus (DILE)**. The underlying mechanism involves its metabolism via the **N-acetyltransferase (NAT)** enzyme. In the liver, procainamide is acetylated to N-acetylprocainamide (NAPA). Patients who are **"slow acetylators"** have a genetic deficiency of this enzyme, leading to the accumulation of the parent drug. This excess drug undergoes alternative oxidative metabolism, forming reactive metabolites that trigger an autoimmune response, typically manifesting as joint pain, fever, and pleuritis. **Analysis of Incorrect Options:** * **A. Amiodarone:** Known for causing pulmonary fibrosis, thyroid dysfunction (hypo/hyperthyroidism), and corneal microdeposits, but not a lupus-like syndrome. * **B. Clonidine:** An alpha-2 agonist used for hypertension; its primary side effects include sedation, dry mouth, and rebound hypertension upon abrupt withdrawal. * **C. Nitroglycerin:** A vasodilator used in angina; common side effects include throbbing headache, flushing, and orthostatic hypotension. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for DILE drugs:** "**S**hip **H**as **P**ushed **M**e" (**S**ulfonamides, **H**ydralazine, **I**soniazid, **P**rocainamide, **P**henytoin, **M**ethyldopa). * **Serology:** DILE is characterized by the presence of **Anti-Histone Antibodies** (95% sensitivity). Unlike systemic lupus (SLE), Anti-dsDNA antibodies are usually absent. * **Prognosis:** Symptoms typically resolve upon discontinuation of the offending drug. * **Procainamide specific:** It has the highest risk of inducing ANA (Antinuclear Antibody) positivity, occurring in up to 80% of patients over time.

Q: Which of the following is least likely to cause an increase in bradykinin production?

Irbesartan. The correct answer is **Irbesartan** because of the fundamental difference in the mechanism of action between ACE inhibitors and Angiotensin II Receptor Blockers (ARBs). **1. Why Irbesartan is correct:** Irbesartan is an **ARB**. ARBs act by selectively blocking the $AT_1$ receptor. Unlike ACE inhibitors, they do not inhibit the Angiotensin-Converting Enzyme (ACE). Since ACE is the same enzyme responsible for the degradation of bradykinin (also known as Kininase II) [1], ARBs do not interfere with bradykinin metabolism. Therefore, they do not cause an increase in bradykinin levels. **2. Why the other options are incorrect:** * **Perindopril & Benazepril:** These are **ACE Inhibitors**. ACE inhibitors prevent the conversion of Angiotensin I to Angiotensin II. Simultaneously, they inhibit the breakdown of bradykinin into inactive peptides [2]. This leads to an accumulation of bradykinin in the lungs and tissues. **3. Clinical Pearls for NEET-PG:** * **The "Cough" Connection:** The accumulation of bradykinin (and substance P) in the lungs is the primary reason why ACE inhibitors cause a **dry, irritating cough** in 5-20% of patients [1]. * **Angioedema:** Increased bradykinin levels are also implicated in the rare but life-threatening side effect of angioedema associated with ACE inhibitors [1]. * **Switching Therapy:** If a patient develops a cough on an ACE inhibitor (like Perindopril), the standard clinical practice is to switch them to an ARB (like Irbesartan), as ARBs are "bradykinin-neutral." * **High-Yield Fact:** ACE is also known as **Kininase II**. Inhibition of this enzyme is what leads to the "Kinin-mediated" side effects of ACE inhibitors [1].

Q: Beta-blockers are contraindicated in which of the following conditions?

All of the above. **Explanation:** Beta-blockers act by antagonizing $\beta_1$, $\beta_2$, and sometimes $\alpha_1$ receptors. While they are cornerstone drugs in chronic stable heart failure, their use is strictly contraindicated in certain acute and specific conditions due to their physiological effects. 1. **Decompensated Congestive Heart Failure (CHF):** In acute decompensation, the heart relies on high sympathetic drive (tachycardia and increased contractility) to maintain cardiac output. Beta-blockers are **negative inotropes**; administering them during this phase can further reduce cardiac output, worsening pulmonary edema and leading to cardiogenic shock. 2. **Asthma:** Non-selective beta-blockers (like Propranolol) block **$\beta_2$ receptors** in the bronchial smooth muscle. This leads to bronchoconstriction and can precipitate a life-threatening asthma attack. Even $\beta_1$-selective blockers should be used with extreme caution. 3. **Variant (Prinzmetal) Angina:** This condition is caused by coronary artery vasospasm. Blocking $\beta_2$ receptors (which mediate vasodilation) leaves **$\alpha_1$ receptors unopposed**, leading to exaggerated vasoconstriction and worsening of the ischemic pain. **High-Yield Clinical Pearls for NEET-PG:** * **Diabetes:** Beta-blockers can mask the warning signs of hypoglycemia (tachycardia/tremors), except for sweating (mediated by cholinergic sympathetic nerves). * **Peripheral Vascular Disease:** They can worsen Raynaud's phenomenon due to unopposed $\alpha$-mediated vasoconstriction. * **Heart Block:** Contraindicated in 2nd or 3rd-degree heart block due to negative dromotropic effects (slowing AV conduction). * **Drug of Choice:** While contraindicated in *acute* failure, **Carvedilol, Metoprolol, and Bisoprolol** are proven to reduce mortality in *chronic* stable heart failure.

Question 1

A patient with hypertension was treated with propranolol. Although it controlled hypertension, it reduced the resting heart rate to 50/min. Which of the following beta-blockers can be used as an effective substitute that does not cause bradycardia?

Accepted Answer

Pindolol

Answer

Labetalol

Answer

Bisoprolol

Answer

Atenolol

Question 2

All of the following are used in the treatment of pulmonary hypertension EXCEPT:

Accepted Answer

Beta blockers

Answer

Endothelin receptor antagonists

Answer

Phosphodiesterase inhibitors

Answer

Calcium channel blockers

Question 3

What is the initial drug of choice for a newly detected hypertension in a 42-year-old male with a history of calcium stones?

Accepted Answer

Chlorthalidone

Answer

Furosemide

Answer

Losartan

Answer

Atenolol

Question 4

Which of the following drugs hyperpolarizes AV nodal tissue, is used in PSVT, and has short-lasting adverse effects?

Accepted Answer

Adenosine

Answer

Verapamil

Answer

Digoxin

Answer

Propranolol

Question 5

Digoxin increases cardiac contractility by directly engaging in which of the following mechanisms?

Accepted Answer

Inhibiting myocardial Na+/K+-ATPase

Answer

Inhibiting myocardial Na+/Ca2+-ATPase

Answer

Activating L-type Ca2+ channels

Answer

Inhibiting cardiac phosphodiesterase

Question 6

Cardioselective beta blockers are contraindicated in which of the following conditions?

Accepted Answer

II & III degree heart block

Answer

COPD

Answer

Asthma

Answer

Tachycardia

Question 7

Which of the following antihypertensives was once used as an antipsychotic?

Accepted Answer

Reserpine

Answer

Atenolol

Answer

Propranolol

Answer

Clonidine

Question 8

Which one of the following drugs is associated with the development of a lupus-like syndrome, especially in patients identified as "slow acetylators"?

Accepted Answer

Procainamide

Answer

Amiodarone

Answer

Clonidine

Answer

Nitroglycerin

Question 9

Which of the following is least likely to cause an increase in bradykinin production?

Accepted Answer

Irbesartan

Answer

Perindopril

Answer

Benzprindopril

Answer

All of the above

Question 10

Beta-blockers are contraindicated in which of the following conditions?

Accepted Answer

All of the above

Answer

Decompensated congestive heart failure

Answer

Asthma

Answer

Variant angina

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?